Trouble falling Asleep?
Researchers at Stanford are partnering with adults who meet the criteria of delayed sleep phase syndrome to investigate potential treatment with Lemborexant. Help advance clinical research and join our study today!
Conducted in Stanford, CA
Compensation Provided
18+ years old
Quick Overview
People who are unable to fall asleep within two hours of desired bedtime
| Study Background Our researchers want to help people fall asleep faster. Stanford has partnered with Eisai and UCSF to explore the potential benefits of a medication called Lemborexant in delayed sleep phase syndrome. Lemborexant is a melatonin agonist currently used to treat insomnia. If you want to go to sleep 2 hours or more before you usually do, but cannot fall asleep any earlier, you may have delayed sleep phase syndrome and could be eligible for this study. Participating in this research study may help investigators to develop better treatments for delayed sleep phase syndrome in the future. Join our compensated study today! |
Additional Information
Delayed Sleep Phase Syndrome is a sleep disorder which includes the following diagnostic criteria:
- Have a desired bedtime that is at least two hours earlier than their actual sleep time
- Person is unable to naturally fall asleep within two hours of desired bedtime
- Sleep disturbances are not better described by a separate sleep condition
This research study will evaluate the effect of Lemborexant on helping people with delayed sleep phase disorder to fall asleep earlier.
You may qualify for this study if you meet the following criteria.
Key Criteria:
Key Criteria:
- 18+ years old
- Trouble falling asleep, causing sleep to be delayed by 2 hours or more
- Sleep problems interfering with your daily life
In total, your participation in the study will last about 2 months and will involve
2-3 initial phone calls/virtual meetings for screening, 4 lab visits, 4 blood draws, 3 ECGs, and 1 DLMO exam.
After screening, if you are eligible, you will enter a baseline period (2 weeks) where you log your daily sleep and wake times and wear an actigraphy watch. You then enter the treatment phase (2 weeks), where you will take either the study medication or a placebo while going to bed at your desired bedtime. Finally, in the withdrawal phase (2 weeks), you stop taking the medication, but continue trying to sleep at your desired bedtime. Lab visits will occur between each of these periods.
2-3 initial phone calls/virtual meetings for screening, 4 lab visits, 4 blood draws, 3 ECGs, and 1 DLMO exam.
After screening, if you are eligible, you will enter a baseline period (2 weeks) where you log your daily sleep and wake times and wear an actigraphy watch. You then enter the treatment phase (2 weeks), where you will take either the study medication or a placebo while going to bed at your desired bedtime. Finally, in the withdrawal phase (2 weeks), you stop taking the medication, but continue trying to sleep at your desired bedtime. Lab visits will occur between each of these periods.
Participants may qualify for compensation up to $1,280.
There is no cost to you for participating in this study.